Rocatinlimab

诺卡替利单抗

Report date: 2026/03/31 20:00:21

Base Information

Drug NameRocatinlimab
Drug Alias NameKHK-4083AMG-451
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor receptor superfamily member 4 inhibitors
TargetsTumor necrosis factor receptor superfamily member 4
Therapy Area/IndicationsPrurigo NodularisAbdominal PainAutoimmune Diseases +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[46] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesKyowa Hakko Kirin Co LtdAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesAmgen IncAmgen Biotechnology Consultation (Shanghai) Co Ltd
Inactive CompaniesKyowa Kirin IncKyowa Kirin Co Ltd
Active IndicationsPrurigo NodularisDermatitis, AtopicAsthma
Inactive IndicationsAbdominal PainAutoimmune DiseasesColonic Diseases +[9] 

Other Information

ATC CodeN/A
Related LinksN/A